Bayer Earnings Top Estimates on Crop Science, Soybean Gains


In its pharmaceutical division, Bayer continued to suffer from generic competition to Xarelto, with sales of the blockbuster blood thinner slumping by 40% in the quarter, as well as eye medicine Eylea. The company is counting on growth from cancer drug Nubeqa and kidney therapy Kerendia, as well as new launches, to return the unit to growth by 2027.



Source link

  • Related Posts

    Tuesday’s primaries will set up midterm matchups for Nebraska, West Virginia

    Tuesday’s primary elections in Nebraska will set the stage for November in a battleground House district, as well as a potentially competitive Senate contest, as Democrats try to win control…

    Qatar Asks Ships to Go Dark at LNG Port in New Safety Measure

    The waters around the Persian Gulf, where the port is located, have faced major security issues during the war in the Middle East that’s now into its third month. A…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Inflation report to show latest prices as fuel costs surge amid Iran war

    Inflation report to show latest prices as fuel costs surge amid Iran war

    The War in Iran Is Another Blow to Russia’s Credibility. Or Is It?

    The War in Iran Is Another Blow to Russia’s Credibility. Or Is It?

    Tax cuts and cost of living help proposed by Labour-linked groups allied to Streeting and Burnham | Labour

    Tax cuts and cost of living help proposed by Labour-linked groups allied to Streeting and Burnham | Labour

    Tuesday’s primaries will set up midterm matchups for Nebraska, West Virginia

    Tuesday’s primaries will set up midterm matchups for Nebraska, West Virginia

    Texas sues Netflix for advertising ‘bait and switch’ and spying

    Texas sues Netflix for advertising ‘bait and switch’ and spying

    Minister Sidhu meets with United Kingdom’s Secretary of State for Business and Trade and President of the Board of Trade Jonathan Reynolds